UK medical device company ANGLE has received FDA clearance for its
Parsortix PC1 system, a first-of-its-kind device that can harvest intact cancer
cells from a patient's blood sample for subsequent analysis. This is a
significant milestone for the company, and it has the potential to
revolutionize the way cancer is detected and managed.
The Parsortix system is a liquid biopsy device, which means that it
can detect cancer cells in the bloodstream without the need for an invasive
tissue biopsy. This is a major advantage, as it is less risky and more
convenient for patients. Additionally, liquid biopsies can be used to monitor
cancer progression and treatment response over time, something that is not
possible with tissue biopsies.
The Parsortix system works by using a microfluidic chamber to
capture cancer cells from the blood sample. The cells are then harvested and
can be used for a variety of downstream assays, such as genetic testing or
immunophenotyping. This information can be used to diagnose cancer, identify
the type of cancer, and determine the best course of treatment.
ANGLE is now looking to commercialize the Parsortix system in the
United States. The company has already partnered with several leading cancer centers
to begin using the device in clinical trials. ANGLE is also working to develop
new assays that can be used with the Parsortix system to detect and monitor a
wider range of cancers.
How the Parsortix system could change the game for cancer detection
The Parsortix system has the potential to revolutionize cancer
detection and management in a number of ways:
·
Earlier
detection: The Parsortix system can
detect cancer cells at earlier stages than traditional tissue
biopsies. This is because cancer cells often shed into the bloodstream
before they can be detected by other methods. Earlier detection of cancer
can lead to better outcomes for patients, as it allows for earlier
treatment intervention.
·
More
convenient and less risky for patients: Liquid
biopsies are less invasive and risky than tissue biopsies. This is because
they do not require surgery or other procedures to collect the
sample. This makes them a more viable option for patients who are not able
to have tissue biopsies, such as those who are elderly or have other
health conditions.
·
Ability
to monitor cancer progression and treatment response: Liquid biopsies can be used to monitor cancer progression and
treatment response over time. This is not possible with tissue
biopsies, as they can only provide a snapshot of the cancer at the time of
the biopsy. The ability to monitor cancer progression and treatment
response can help doctors to make better decisions about treatment.
Overall, the Parsortix system has the potential to revolutionize cancer detection and management by making it possible to detect cancer earlier and more conveniently, and to monitor cancer progression and treatment response over time. This could lead to better outcomes for patients and improved cancer survival rates.
Comments
Post a Comment
any suggestion on my side